HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Knowledge of benefits, harms of medical marijuana for cancer ‘far from complete’
• Can medical marijuana replace opioids to relieve cancer pain?
• Vale Col. Coltman! Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Trove of brain cancer data available for study through Georgetown platform
• Genetic mutations could help guide treatments for appendix cancer
• Survivin may be target for immunotherapies in several malignancies
• Chemo Buddies provide comfort, hope to patients with cancer
• E-cigarette use doubles heart attack risk
• Lower stomach cancer increasing among young non-Hispanic whites
• NCCN issues first guidelines for gestational trophoblastic neoplasia
• Removal of ‘cancer’ label could reduce overdiagnosis, overtreatment of low-risk disease
• Magnetic resonance spectroscopy-based method may help predict prostate cancer aggressiveness
• NHLBI grant to fund research toward prevention of cancer-related venous thromboembolism
• Blood-based tests comparable to bone marrow biopsy for diagnosing, monitoring multiple myeloma
• Trial to assess ibrutinib-cirmtuzumab combination for B-cell malignancies
• Thermal ablation effective in early-stage lung cancer
• Novel wireless device shows potential for detecting cardiovascular disease among childhood cancer survivors
• Trump’s latest drug pricing plan may offer benefits to patients, but faces obstacles
• Trial to assess CAR T-cell therapy for certain lymphomas, leukemias
• Local radiotherapy extends survival for certain men with metastatic prostate cancer
• Certain risk factors warrant breast cancer screening at age 30
• Consideration of CV health important during breast cancer treatment
• Efficacy, safety must guide treatment sequencing decisions in chronic myeloid leukemia
• Once-weekly, conventional breast radiotherapy yield similarly low long-term adverse effects
• Whole-breast radiation reduces local recurrence in favorable-risk ductal carcinoma in situ
• Proton therapy for pediatric brain tumors yields better cognitive outcomes than X-ray therapy
• Training program improves oncologists’ LGBT-related knowledge, attitudes
• Risk model may predict survival among African-American women with breast cancer
• Rivaroxaban effective as thromboprophylaxis during anticancer treatment
• Pembrolizumab demonstrates ‘robust’ activity in relapsed, refractory primary mediastinal large B-cell lymphoma
• Autologous gene therapy shows promise for sickle cell disease
• Checkpoint inhibitors enhance CAR T-cell therapy in relapsed B-cell acute lymphoblastic leukemia
• Sibling transplantation with reduced-intensity conditioning fails to improve AML outcomes
• First-line pembrolizumab a new standard for recurrent, metastatic head and neck squamous cell carcinoma
• Adjuvant ado-trastuzumab emtansine provides ‘transformative’ benefit for certain patients with HER2-positive breast cancer
• Novel risk stratification model outperforms standard prediction tools for myelodysplastic syndrome
• CT scans may increase risk for brain cancer among children
• ‘Soft’ chemotherapy delays breast cancer progression for elderly
• High BMI in early adulthood may reduce risk for premenopausal breast cancer
• Examination of breast tissue recommended after gender-confirming mastectomy
• Risks of breast cancer surgery may outweigh benefits for nursing home residents
• Estrogen after oophorectomy does not increase breast cancer risk
• 14 million additional adolescents needed to reach HPV vaccination goal
• High-dose vitamin D may not prevent cancer
• H. pylori therapy lowers incidence of metachronous gastric cancer
• Germline mutations common among patients with pancreatic cancer, previous cancer history
• Adjuvant chemotherapy improves OS in rectal cancer
• Gastroenteropancreatic neuroendocrine tumor recurrence often occurs late
• Women with disabilities less likely to undergo cervical cancer screening
• Apatinib shows promise for ovarian cancer
• Second cancers increasingly common among HPV-related cancer survivors
• Researchers identify promising treatment regimen for head and neck squamous cell carcinoma
• Positive initial margins associated with poor DFS following total laryngectomy
• Guideline supports shorter radiation therapy option in prostate cancer
• Bone scan software predicts survival for metastatic prostate cancer
• Cabozantinib improved time to deterioration, but not quality of life for renal cell carcinoma
• Robotic-assisted cystectomy noninferior to open procedure
• Risk does not dictate real-world surveillance frequency for bladder cancer
• Rivaroxaban shows ‘no benefit, excess risk’ for antiphospholipid syndrome
• Venous thromboembolism decreases physical function among women
• End-of-life care often intense among hematopoietic stem cell transplant recipients
• Ponatinib shows promise for chronic myeloid leukemia in chronic phase
• Azacitidine-nivolumab combination safe, effective in certain patients with acute myeloid leukemia
• Ivosidenib induces durable responses in relapsed, refractory acute myeloid leukemia
• Interim PET scan predicts survival in aggressive lymphoma
• ‘Genomic calculator’ may better predict outcomes in myeloproliferative neoplasms
• Stereotactic body radiation therapy safely provides tumor control for early-stage lung cancer
• Detection of ROS1 rearrangement in lung cancer remains ‘complex’
• Capizzi-style methotrexate improves survival in pediatric T-cell acute lymphoblastic leukemia
• Pediatric liver cancer may lead to brain metastases
• High-dose steroids for treatment-induced hypophysitis reduce melanoma survival
• Pembrolizumab for melanoma may cause antiphospholipid syndrome
• Patients’ sex may impact efficacy of immune checkpoint inhibitors
• Universal genetic testing feasible at time of pancreatic cancer diagnosis
• Public lacks awareness of link between physical activity, cancer risk
• High-dose chemotherapy improves survival in Ewing sarcoma
• Association between screening-detected thyroid cancers, radiation exposure ‘unlikely’ in Fukushima children
• Patients with cancer may be at risk for opioid misuse
• Circulating tumor cells associated with late breast cancer recurrence
• Radiotherapy, surgery comparable options for oropharyngeal cancer
• Increase in mortality with daily aspirin attributable to cancer
• Path of Medicare Advantage changing
• FDA approves Vitrakvi for solid tumors with NTRK gene fusion
• FDA approves glasdegib for older patients with acute myeloid leukemia
• FDA grants priority review to quizartinib for FLT3-ITD acute myeloid leukemia
• FDA grants breakthrough therapy designation to UGN-101 for urothelial cancer
• FDA approves Adcetris for first-line treatment of peripheral T-cell lymphoma
• FDA approves Venclexta for older patients with acute myeloid leukemia
• FDA approves Promacta for first-line treatment of severe aplastic anemia
• AACR report: Bipartisan federal commitment fuels biomedical cancer research
• ASH's comprehensive guidelines aim to improve management of venous thromboembolism
• Roswell Park Comprehensive Cancer Center part of first biotech venture between US, Cuba
• Abramson Cancer Center becomes member institution of National Comprehensive Cancer Network
• International Society of Geriatric Oncology presents award to Sidney Kimmel Cancer Center researcher
• Pembrolizumab extends OS in PD-L1-expressing esophageal cancers